Cargando…
In vivo characterization of the physicochemical properties of TLR agonist delivery that enhance vaccine immunogenicity
The efficacy of vaccine adjuvants such as Toll-like receptor agonists (TLRa) can be improved through formulation and delivery approaches. Here, we attached small molecule TLR-7/8a to polymer scaffolds (polymer-TLR-7/8a) and evaluated how varying physicochemical properties of the TLR-7/8a and polymer...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842712/ https://www.ncbi.nlm.nih.gov/pubmed/26501954 http://dx.doi.org/10.1038/nbt.3371 |
_version_ | 1783304951726866432 |
---|---|
author | Lynn, Geoffrey M. Laga, Richard Darrah, Patricia A. Ishizuka, Andrew S. Balaci, Alexandra J. Dulcey, Andrés E. Pechar, Michal Pola, Robert Gerner, Michael Y. Yamamoto, Ayako Buechler, Connor R. Quinn, Kylie M. Smelkinson, Margery G. Vanek, Ondrej Cawood, Ryan Hills, Thomas Vasalatiy, Olga Kastenmuller, Kathrin Francica, Joseph R. Stutts, Lalisa Tom, Janine K. Ryu, Keun Ah Esser-Kahn, Aaron P. Etrych, Tomas Fisher, Kerry D. Seymour, Leonard W. Seder, Robert A. |
author_facet | Lynn, Geoffrey M. Laga, Richard Darrah, Patricia A. Ishizuka, Andrew S. Balaci, Alexandra J. Dulcey, Andrés E. Pechar, Michal Pola, Robert Gerner, Michael Y. Yamamoto, Ayako Buechler, Connor R. Quinn, Kylie M. Smelkinson, Margery G. Vanek, Ondrej Cawood, Ryan Hills, Thomas Vasalatiy, Olga Kastenmuller, Kathrin Francica, Joseph R. Stutts, Lalisa Tom, Janine K. Ryu, Keun Ah Esser-Kahn, Aaron P. Etrych, Tomas Fisher, Kerry D. Seymour, Leonard W. Seder, Robert A. |
author_sort | Lynn, Geoffrey M. |
collection | PubMed |
description | The efficacy of vaccine adjuvants such as Toll-like receptor agonists (TLRa) can be improved through formulation and delivery approaches. Here, we attached small molecule TLR-7/8a to polymer scaffolds (polymer-TLR-7/8a) and evaluated how varying physicochemical properties of the TLR-7/8a and polymer carrier influenced the location, magnitude and duration of innate immune activation in vivo. Particle formation by polymer-TLR-7/8a was critical for restricting adjuvant distribution and prolonging activity in draining lymph nodes. The improved pharmacokinetic profile by particulate polymer-TLR-7/8a was also associated with reduced morbidity and enhanced vaccine immunogenicity for inducing antibodies and T cell immunity. We extended these findings to the development of a modular platform in which protein antigens are site-specifically linked to temperature-responsive polymer-TLR-7/8a adjuvants that self-assemble into immunogenic particles at physiologic temperatures in vivo. Our findings provide a chemical and structural basis for optimizing adjuvant design to elicit broad-based antibody and T cell responses with protein antigens. |
format | Online Article Text |
id | pubmed-5842712 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
record_format | MEDLINE/PubMed |
spelling | pubmed-58427122018-03-08 In vivo characterization of the physicochemical properties of TLR agonist delivery that enhance vaccine immunogenicity Lynn, Geoffrey M. Laga, Richard Darrah, Patricia A. Ishizuka, Andrew S. Balaci, Alexandra J. Dulcey, Andrés E. Pechar, Michal Pola, Robert Gerner, Michael Y. Yamamoto, Ayako Buechler, Connor R. Quinn, Kylie M. Smelkinson, Margery G. Vanek, Ondrej Cawood, Ryan Hills, Thomas Vasalatiy, Olga Kastenmuller, Kathrin Francica, Joseph R. Stutts, Lalisa Tom, Janine K. Ryu, Keun Ah Esser-Kahn, Aaron P. Etrych, Tomas Fisher, Kerry D. Seymour, Leonard W. Seder, Robert A. Nat Biotechnol Article The efficacy of vaccine adjuvants such as Toll-like receptor agonists (TLRa) can be improved through formulation and delivery approaches. Here, we attached small molecule TLR-7/8a to polymer scaffolds (polymer-TLR-7/8a) and evaluated how varying physicochemical properties of the TLR-7/8a and polymer carrier influenced the location, magnitude and duration of innate immune activation in vivo. Particle formation by polymer-TLR-7/8a was critical for restricting adjuvant distribution and prolonging activity in draining lymph nodes. The improved pharmacokinetic profile by particulate polymer-TLR-7/8a was also associated with reduced morbidity and enhanced vaccine immunogenicity for inducing antibodies and T cell immunity. We extended these findings to the development of a modular platform in which protein antigens are site-specifically linked to temperature-responsive polymer-TLR-7/8a adjuvants that self-assemble into immunogenic particles at physiologic temperatures in vivo. Our findings provide a chemical and structural basis for optimizing adjuvant design to elicit broad-based antibody and T cell responses with protein antigens. 2015-10-26 2015-11 /pmc/articles/PMC5842712/ /pubmed/26501954 http://dx.doi.org/10.1038/nbt.3371 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Lynn, Geoffrey M. Laga, Richard Darrah, Patricia A. Ishizuka, Andrew S. Balaci, Alexandra J. Dulcey, Andrés E. Pechar, Michal Pola, Robert Gerner, Michael Y. Yamamoto, Ayako Buechler, Connor R. Quinn, Kylie M. Smelkinson, Margery G. Vanek, Ondrej Cawood, Ryan Hills, Thomas Vasalatiy, Olga Kastenmuller, Kathrin Francica, Joseph R. Stutts, Lalisa Tom, Janine K. Ryu, Keun Ah Esser-Kahn, Aaron P. Etrych, Tomas Fisher, Kerry D. Seymour, Leonard W. Seder, Robert A. In vivo characterization of the physicochemical properties of TLR agonist delivery that enhance vaccine immunogenicity |
title | In vivo characterization of the physicochemical properties of TLR agonist delivery that enhance vaccine immunogenicity |
title_full | In vivo characterization of the physicochemical properties of TLR agonist delivery that enhance vaccine immunogenicity |
title_fullStr | In vivo characterization of the physicochemical properties of TLR agonist delivery that enhance vaccine immunogenicity |
title_full_unstemmed | In vivo characterization of the physicochemical properties of TLR agonist delivery that enhance vaccine immunogenicity |
title_short | In vivo characterization of the physicochemical properties of TLR agonist delivery that enhance vaccine immunogenicity |
title_sort | in vivo characterization of the physicochemical properties of tlr agonist delivery that enhance vaccine immunogenicity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842712/ https://www.ncbi.nlm.nih.gov/pubmed/26501954 http://dx.doi.org/10.1038/nbt.3371 |
work_keys_str_mv | AT lynngeoffreym invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT lagarichard invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT darrahpatriciaa invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT ishizukaandrews invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT balacialexandraj invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT dulceyandrese invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT pecharmichal invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT polarobert invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT gernermichaely invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT yamamotoayako invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT buechlerconnorr invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT quinnkyliem invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT smelkinsonmargeryg invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT vanekondrej invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT cawoodryan invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT hillsthomas invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT vasalatiyolga invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT kastenmullerkathrin invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT francicajosephr invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT stuttslalisa invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT tomjaninek invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT ryukeunah invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT esserkahnaaronp invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT etrychtomas invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT fisherkerryd invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT seymourleonardw invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity AT sederroberta invivocharacterizationofthephysicochemicalpropertiesoftlragonistdeliverythatenhancevaccineimmunogenicity |